ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study

Ying, Li; Suyun, Ji; Yanhua, Liang; Yunsheng, Liang; Li, Deng; Lin, Dang; Chengzhi, Lv; Bingjiang, Lin; Furen, Zhang; Wendi, Shi; Jinnan, Li; Yu, Dong; Guanshen, Dou; Shi, Yuling*南方医科大学; 山东省医学科学院; 同济大学
ADVANCES IN THERAPY2023-12DOI: 10.1007/s12325-023-02672-1
5阅读
引用收藏
分享

摘要

IntroductionPsoriasis, an incurable chronic inflammatory disease, affects over 6 million people in China. Ixekizumab, a monoclonal antibody against interleukin-17A, has demonstrated efficacy and safety for the treatment of moderate-to-severe plaque psoriasis, although limited data are available regarding its use in routine clinical practice in China. We investigated the real-world application of ixekizumab in China.MethodsAdults (>= 18 years) with moderate-to-severe plaque psoriasis prescribed ixekizumab in routine clinical practice were enrolled in this prospective, observational, single-arm, multicenter, post-marketing surveillance study. The primary endpoint was the safety of ixekizumab at week 12. The effectiveness of ixekizumab, based on the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI), was assessed as a secondary endpoint.ResultsIn total, 666 patients were enrolled; 663 were included in the safety analysis, and 612 in the effectiveness analysis. At least one adverse event (AE) was reported by 42.7% (283/663) of patients, most of which were mild (242/283, 85.5%), and 32.7% (217/663) of patients reported AEs related to study treatment. The most frequently reported AEs were injection site reactions. AEs led to discontinuation in five patients (0.8%). Only three patients had a serious AE. Mean +/- standard deviation (SD) change from baseline in PASI score was reduction in 10.79 +/- 9.55 at week 2 and 16.80 +/- 12.15 at week 12. At week 2, 63.7% of patients achieved PASI 50. At week 12, 93.2%, 77.4%, and 45.1% of patients achieved PASI 75, PASI 90, and PASI 100, respectively. Mean +/- SD change from baseline in DLQI was reduction in 5.91 +/- 6.27 at week 2 and 9.76 +/- 7.16 at week 12. DLQI 0/1 was achieved by 19.8% and 59.9% of patients at week 2 and 12, respectively.ConclusionIxekizumab was well tolerated and effective in real-world clinical practice in Chinese adults with moderate-to-severe plaque psoriasis.

学科与关键词

关键词
EfficacyIxekizumabPsoriasisReal worldSafety
相关
加载中…
  • Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
    Chinese Medical Journal, 2020, 133(22): 2665-2673.
  • Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study
    Ding, Yangfeng; Li, Wei; Guan, Xin; Liu, Na; Zhou, Ying; Li, Gaojie; Wang, Xiaohua; Wang, Zhidong; Xiao, Xiao; Yang, Bin*; Lv, Chengzhi*; Zhang, Chunlei*; Shi, Yuling*CTS-Clinical and Translational Science, 2023, 16(10): 1803-1814.被引 1
  • A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China
    Wang, Yu; Wang, Xiaohua; Yu, Yixin; Yuan, Liyan; Yu, Xiaoling; Yang, Bin*Dermatologic Therapy, 2021, 34(5): e15081.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
ADVANCES IN THERAPY
发表日期
2023-12
卷期
第 40 卷, 第 12 期
页码
5464-5474
DOI
10.1007/s12325-023-02672-1
语言
ENGLISH
成果收录
SCIE
资助标注
Eli Lilly and Company; National Natural Science Foundation of China [82073429, 82273510, 82203913]; Innovation Program of Shanghai Municipal Education Commission [2019-01-07-00-07-E00046]; Clinical Research Plan of SHDC [SHDC2020CR1014B]; Program of Shanghai Academic Research Leader [20XD1403300]

作者

  • Y

    Ying, Li (第一作者)

    tongji univ

  • S

    Suyun, Ji

    southern med univ

查看全部 14 位作者收起作者
  • Y

    Yanhua, Liang

  • Y

    Yunsheng, Liang

  • L

    Li, Deng

    southern med univ

  • L

    Lin, Dang

  • C

    Chengzhi, Lv

  • B

    Bingjiang, Lin

  • F

    Furen, Zhang

    shandong acad med sci · shandong prov hosp

  • W

    Wendi, Shi

  • J

    Jinnan, Li

  • Y

    Yu, Dong

  • G

    Guanshen, Dou

  • S

    Shi, Yuling (通讯)

    tongji univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417